Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Jiangsu Simcere Pharmaceutical Co: Clinical Trials & FDA Approval Profile

Jiangsu Simcere Pharmaceutical Co (Global / Institutional) sponsors 16 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 6 active protocols (1 recruiting now), 5 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)6.3%
Median Closed Enrollment vs National (145 pts)156 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Jiangsu Simcere Pharmaceutical Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)16
Active Pipeline (Recruiting Now)6 (1)
Completed vs Stopped Early5 / 1 (6.3%)
Median Closed Actual Enrollment156 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Jiangsu Simcere Pharmaceutical Co
Hospital Research SiteLocationShared Protocols
The first affiliated hospital of Zhengzhou UniversityZhengzhou, Henan5
Zhejiang Provincial People's HospitalHangzhou, Zhejiang4
The First Hospital of Jilin UniversityChangchun, Jilin4

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Jiangsu Simcere Pharmaceutical Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06680921A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)Phase IIIACTIVE NOT RECRUITING
NCT04908787A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian CancerPhase IIICOMPLETED
NCT06010693A Study of Daridorexant in Chinese Patients With Insomnia DisorderPhase IIICOMPLETED
NCT05506176A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants WithPhase II/IIICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Jiangsu Simcere Pharmaceutical Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI